EMD-37648
SARS-CoV-2 EG.5.1 spike glycoprotein (1-up state)
EMD-37648
Single-particle3.34 Å
Deposition: 03/10/2023Map released: 24/04/2024
Last modified: 17/07/2024
Sample Organism:
Severe acute respiratory syndrome coronavirus 2
Sample: SARS-COV-2 EG.5.1 spike glycoprotein
Deposition Authors: Nomai T
,
Anraku Y ,
Kita S ,
Hashiguchi T ,
Maenaka K
Sample: SARS-COV-2 EG.5.1 spike glycoprotein
Deposition Authors: Nomai T
,
Anraku Y ,
Kita S ,
Hashiguchi T ,
Maenaka K
Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant.
Tsujino S ,
Deguchi S,
Nomai T ,
Padilla-Blanco M,
Plianchaisuk A ,
Wang L,
Begum MM,
Uriu K,
Mizuma K,
Nao N,
Kojima I,
Tsubo T,
Li J,
Matsumura Y,
Nagao M,
Oda Y,
Tsuda M,
Anraku Y ,
Kita S ,
Yajima H,
Sasaki-Tabata K,
Guo Z,
Hinay Jr AA,
Yoshimatsu K ,
Yamamoto Y,
Nagamoto T,
Asakura H,
Nagashima M,
Sadamasu K,
Yoshimura K,
Nasser H,
Jonathan M,
Putri O ,
Kim Y,
Chen L,
Suzuki R,
Tamura T ,
Maenaka K ,
Irie T,
Matsuno K,
Tanaka S,
Ito J,
Ikeda T ,
Takayama K ,
Zahradnik J,
Hashiguchi T ,
Fukuhara T ,
Sato K
(2024) Microbiol Immunol
,
Deguchi S,
Nomai T ,
Padilla-Blanco M,
Plianchaisuk A ,
Wang L,
Begum MM,
Uriu K,
Mizuma K,
Nao N,
Kojima I,
Tsubo T,
Li J,
Matsumura Y,
Nagao M,
Oda Y,
Tsuda M,
Anraku Y ,
Kita S ,
Yajima H,
Sasaki-Tabata K,
Guo Z,
Hinay Jr AA,
Yoshimatsu K ,
Yamamoto Y,
Nagamoto T,
Asakura H,
Nagashima M,
Sadamasu K,
Yoshimura K,
Nasser H,
Jonathan M,
Putri O ,
Kim Y,
Chen L,
Suzuki R,
Tamura T ,
Maenaka K ,
Irie T,
Matsuno K,
Tanaka S,
Ito J,
Ikeda T ,
Takayama K ,
Zahradnik J,
Hashiguchi T ,
Fukuhara T ,
Sato K
(2024) Microbiol Immunol